JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i4.14781ArticleResearch on Drug Resistance Mechanisms and Countermeasures of Targeted Therapy for Colorectal Cancer Based on Next-Generation Sequencinghttps://artdesignp.com/journal/JCNR/10/4/10.26689/jcnr.v10i4.14781LiMengyi20261042026-04-30Colorectal cancer, a malignant gastrointestinal tumor with high morbidity and mortality, has long been plagued by difficulties in treatment and high recurrence rates, seriously threatening patients’ lives and health. With the continuous development of molecular biology technology, targeted therapy has emerged and shown great value in improving the survival and prognosis of patients with colorectal cancer. However, drug resistance is common in clinical practice, which directly impairs therapeutic efficacy. Next-Generation Sequencing (NGS), a high-efficiency and high-throughput molecular detection technology, can deeply analyze the genomic characteristics of tumors, accurately identify relevant molecular targets, and provide important support for the study of drug resistance mechanisms and the formulation of individualized countermeasures. This paper discusses the drug resistance mechanisms of targeted therapy for colorectal cancer based on NGS and the corresponding countermeasures, aiming to provide reference for relevant practitioners.

Wang B, Yang Y, Wei Y, et al., 2025, Research Progress on Biomarkers Related to Targeted Therapy of Colorectal Cancer. Chinese Journal of Gerontology, 45(11): 2792–2798.

Zhang H, Bu J, 2024, Drug Resistance Mechanisms and Potential Solutions of Targeted Therapy for Colorectal Cancer. Chinese Journal of Practical Surgery, 44(07): 774–780.

Yuan Z, Lai M, 2024, Molecular Classification of Colorectal Cancer and Its Relationship with Immunotherapy and Targeted Therapy. Chinese Journal of Clinical and Experimental Pathology, 40(06): 561–566.

Li R, Han Z, 2023, Research Progress of Immunotherapy and Targeted Therapy for Colorectal Cancer. Journal of Qiqihar Medical University, 44(10): 979–983.

Shi L, Ji W, 2023, Research Progress on the Role of EMT in CRC and Targeted Therapy. Chinese Bulletin of Life Sciences, 35(04): 463–471.

Guo H, Zhou H, Zhu X, et al., 2022, Research Progress of Molecular Targeted Therapy for Colorectal Cancer. Oncology Progress, 20(19): 1950–1953.

Zuo D, Zhang F, 2022, Research Progress of SHP2 Targeted Therapy in Anti-Tumor Therapy. Modern Oncology, 30(19): 3593–3598.

Tang P, Du Q, Wang M, et al., 2022, Research Progress of Targeted Therapy for Metastatic Colorectal Cancer with HER2 Gene Amplification or Overexpression. China Practical Rational Drug Use, 19(09): 29–34.

Zhang C, Xue Y, Chen D, et al., 2022, Research Progress of Chemotherapy and Targeted Therapy for Colorectal Cancer. Practical Pharmacy and Clinical Remedies, 25(05): 453–458.

Zhou L, 2022, Research Progress of Targeted Drugs for Colorectal Cancer. Journal of Yan’an University (Medical Sciences), 20(01): 1–9.

Li J, Mao Y, Zhang X, et al., 2021, Research on the Correlation Between Circulating Tumor DNA and Targeted Therapy and Drug Resistance Mechanisms in Metastatic Colorectal Cancer. Practical Preventive Medicine, 28(12): 1450–1454.

Li C, Huang X, Wang P, 2021, Research Progress of Related Molecular Targets and Targeted Therapy for Colorectal Cancer. Shandong Medical Journal, 61(17): 108–112.

Pan S, Fang J, 2019, Current Status and Prospects of Targeted Therapy for Colorectal Cancer. Chinese Journal of Gastroenterology, 24(11): 678–682.

Xue Y, Li Q, 2017, Targeted Therapy and Drug Resistance Mechanisms of Colorectal Cancer. World Clinical Drugs, 38(11): 721–726.

Xu K, Chen G, Peng H, 2017, Research Progress on Drug Resistance Mechanisms of Targeted Therapy for Colorectal Cancer. International Journal of Pharmaceutical Research, 44(05): 402–408.